Not only that, monotherapy with AHP has also been demonstrated to improve liver fibrosis in CHB patients with normal or minimally elevated alanine transaminase levels and early liver fibrosis by histological assessment and noninvasive measurement after 48 weeks of treatment (Xiao et al., 2022), suggesting that AHP alone or in combination with antiviral drugs can resolve fibrosis, but its effect on liver-related clinical outcomes requires further study. This evidence concerns the gene GPT and anhaptoglobinemia.